By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Ionis Pharmaceuticals 

2855 Gazelle Court

Carlsbad  California  92010  U.S.A.
Phone: 760-931-9200 Fax: n/a


Ionis Pharmaceuticals, Inc., located in the North San Diego County city of Carlsbad, was founded in 1989 to create advanced, novel medicines to treat complex and challenging diseases. We are the pioneer in the discovery and development of antisense drugs with more than 1300 patents.

Ionis is a challenging, motivating and rewarding environment designed to foster innovation and scientific excellence. Our founding goals have changed little in over 27 years and our success is a direct result of our outstanding employees. We are interested in bringing together individuals with different skill sets into this creative environment to be part of a productive team. Join us and experience our unique culture while you develop and expand your career.

See Collaborations

Key Statistics

Ownership: Public

Web Site: Ionis Pharma
Employees: 400+
Symbol: IONS


Company News
Ionis Pharma (IONS) To Host R&D Day 6/23/2016 7:03:23 AM
5 Biotech Stocks at Bargain Basement Prices 6/21/2016 7:42:08 AM
Ionis Pharma (IONS)'s Pain Propels Alnylam (ALNY) to Gain $1.5 Billion in Market Cap 6/1/2016 6:47:34 AM
Ionis Pharma (IONS) Plummets After GlaxoSmithKline (GSK) Opts Not to Initiate Phase III Study for Amyloid Cardiomyopathy Drug 5/26/2016 5:53:24 AM
Ionis Pharma (IONS) And MD Anderson Cancer Center Form Strategic Alliance To Advance Novel Cancer Therapeutics 5/23/2016 6:52:37 AM
Ionis Pharma (IONS) Provides Corporate Update At 2016 Annual Meeting Of Stockholders 5/5/2016 7:48:23 AM
Ionis Pharma (IONS) Reports Financial Results And Highlights For First Quarter 2016 5/4/2016 7:26:10 AM
Ionis Pharma (IONS), Kastle Forge $95 Million KYNAMRO Deal 5/3/2016 5:54:25 AM
Webcast Alert: Ionis Pharma (IONS)' First Quarter 2016 Financial Results Conference Call 4/22/2016 6:33:15 AM
Ionis Pharma (IONS) Reports Data Update From Nusinersen Phase 2 Study In Infants With Spinal Muscular Atrophy And Reviews Neurological Disease Franchise 4/20/2016 11:18:04 AM